EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nanobodies Outperform Antibodies – Rapid Functionalization with Equal In Vivo Targeting Properties

Carina Jung, Michael Fichter, Jennifer Oberländer, Jenny Schunke, Vanessa Bolduan, Paul Schneider, Jinhong Kang, Kaloian Koynov iD, Volker Mailänder iD, Katharina Landfester iD

Advanced Materials · 2024

DOI: 10.1002/adma.202412563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, 2024. Verfasst von Carina Jung und 9 weiteren Autor:innen. Beteiligte Einrichtung: Max Planck Institute for Polymer Research, Ackermannweg 10, 55128, Mainz, Germany. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Dendritic Cells. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Highly specific targeting of dendritic cells in vivo is crucial for the development of effective tumor nanovaccines. This group recently presented an antibody‐functionalized nanocarrier system able to maintain its targeting properties when transferred from in vitro to in vivo studies. However, producing this system requires long synthesis times and involves high expenses due to the involved site‐specific enzymatic multi‐step modification procedure of the antibody. Consequently, improving the previously proposed system is necessary in order to accelerate the development. Here, a novel system utilizing nanobodies for the targeting of dendritic cells is presented. A C‐terminal cysteine tag facilitates an easy attachment of the nanobody to the nanocarrier via a thiol‐maleimide conjugation technique. This reduces the functionalization time from several days to mere hours. Using in vitro and in vivo assays, it is shown that the optimized system possesses equal targeting properties as the antibody‐based system. As a result, nanobodies and the coupling chemistry are found to be a superior strategy for the in vivo targeting of dendritic cells when compared to antibodies, due to their rapid attachment to nanocarriers and equal targeting specificity. This would replace antibodies as the current “gold standard” of targeting moieties.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesDendritic CellsAnimalsMiceMaleimidesHumansNanoparticles

Stichwörter der Autor:innen

dendritic cell targetingnanobodynanocarrier

Substanzen

Single-Domain AntibodiesMaleimidesmaleimide

Autor:innen und Institutionen

  • Max Planck Institute for Polymer Research, Ackermannweg 10, 55128, Mainz, Germany.
  • Department of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstr. 1, 55131, Mainz, Germany.

ORCID-Profile: Kaloian Koynov, Volker Mailänder, Katharina Landfester

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Jung, C., Fichter, M., Oberländer, J., Schunke, J., Bolduan, V., Schneider, P., Kang, J., Koynov, K., Mailänder, V., & Landfester, K. (2024). Nanobodies Outperform Antibodies – Rapid Functionalization with Equal In Vivo Targeting Properties. Advanced Materials. https://doi.org/10.1002/adma.202412563

Vancouver

Jung C, Fichter M, Oberländer J, Schunke J, Bolduan V, Schneider P, et al. Nanobodies Outperform Antibodies – Rapid Functionalization with Equal In Vivo Targeting Properties. Advanced Materials. 2024. doi:10.1002/adma.202412563

BibTeX
@article{Jung2024,
  author = {Jung, Carina and Fichter, Michael and Oberländer, Jennifer and Schunke, Jenny and Bolduan, Vanessa and Schneider, Paul and Kang, Jinhong and Koynov, Kaloian and Mailänder, Volker and Landfester, Katharina},
  title = {Nanobodies Outperform Antibodies – Rapid Functionalization with Equal In Vivo Targeting Properties},
  journal = {Advanced Materials},
  year = {2024},
  doi = {10.1002/adma.202412563}
}
Kostenlos starten →